Currently browsing: Guest Blogs

Assorted News from the Last Week: Data shows that childhood cancer survivors were much more likely to develop an aging-associated health condition before the age of 65, with earlier onset, compared with the general population, according to a modeling study. Nearly all cancer treatments for children pose some short- or long-term risk for development of cardiovascular disease and that pediatric patients with cancer may be especially vulnerable to cardiovascular disease because of young age at treatment and expected long life span afterward. Childhood cancer survivors were also at greater risk of developing melanoma. High costs among factors in Malaysia behind [...] Read more

Assorted News from the Last Week: CAC2 Member Blog from Stan Robbins--Awareness & Entertainment Opportunity: Audrey’s Children Childhood cancer survivors have a more than two-fold increased risk of developing melanoma during their lifetime, compared to the general population, as well as a two-fold increased risk of death associated with a melanoma diagnosis. Suicidal ideation significantly higher among childhood cancer survivors. Newborns with heart defects may face a higher risk of developing childhood cancer. New therapeutic approach shows promise for pediatric high-grade gliomas. New NCI Pediatric Preclinical In Vivo Testing Consortium (PIVOT) study data are in the CCDI Data Ecosystem. The [...] Read more

Assorted News from the Last Week: The Coalition Against Childhood Cancer announced plans to hold its 2025 Annual Summit, hosted by Children’s National Hospital in Washington DC and presented by Day One Biopharmaceuticals on June 15-17. A group of organizations, including CAC2 Supporting Organization Servier, announced a collaborative initiative, Access Cancer Treatment (ACT) for Children. The initiative is aligned with the WHO CureAll framework to address disparities in pediatric cancer care in LMICs. Cognitive-behavioral stress management relieves anxiety, depression, and post-traumatic stress disorder in parents of pediatric acute myeloid leukemia patients. President Trump highlights the increased diagnosis of childhood cancer [...] Read more

Assorted News from the Last Week: Thanks to all for a fantastic Action Day on February 28.  348 advocates from 40 states participated and shared their stories in 222 meetings, asking for congressional support for important legislation and funding for childhood cancer. Celebrating collaborative achievement: CAC2 Member Arms Wide Open Childhood Cancer Foundation and Supporting Member The Brain Bodega are launching a pilot program that offers personalized academic support for childhood/teen cancer fighters, survivors, and siblings. The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers: A Review Study shows possible links between PFAS [...] Read more

Assorted News from the Last Week: The Childhood Cancer Data Initiative (CCDI) is piloting data federation with Kids First Data Resource Center, the Pediatric Cancer Data Commons, St. Jude Cloud, and the Treehouse Childhood Cancer Data Initiative. These resources provide information about genomic, clinical, imaging, and biospecimen data in these data sets. This list will expand as more organizations implement CCDI’s data federation API. How genetics shape blood proteins during development from childhood to adolescence. Penn State's THON sets record, raises over $17 million for pediatric cancer research. Allogeneic approach unlocks CAR T cell benefits in solid tumors. Using the [...] Read more

Assorted News from the Last Week: Leo Messi, Alejandra & Richard Gere, Princess Dina supporting OncoThon for childhood cancer research joined the best and the brightest scientists, advocates, and allies to support Oncothon 2025. The immunotherapy drug blinatumomab (Blincyto) is already a standard treatment for some people with acute lymphoblastic leukemia (ALL). Following positive results from a large clinical trial, it’s now expected to become part of the standard initial treatment for many children with the disease. Factors driving stark inequalities for survival rates for children with cancer in low and middle-income countries and how to narrow that survival gap. [...] Read more

Assorted News from the Last Week: CAC2 Member Annette Logan-Parker (Cure 4 the Kids Foundation) explains why she joined the CAC2 Innovation Council. A research paper by Dr. Anahita Fathi Kazerooni, Dr. Adam Kraya, and other colleagues, published in the prestigious Nature Communications Journal, sheds new light on the complexities of pediatric low-grade gliomas. People with cancer are living longer than everopens in a new tab or window, but many of them have to deal with long-lasting effects of the disease and treatment. Pediatric tumors are often driven by one or two spontaneous mutations, whereas adult tumors can have hundreds [...] Read more

Assorted News from the Last Week: A recent study indicates that children and young adults with cancer face an elevated risk of dying if they live in previously redlined neighborhoods—residential areas marked in the 1920s–1930s by lenders as undesirable for mortgage loans due to their racial demographics. International convention: Defeating childhood and adolescent cancer and reducing global disparities. Landscape of global pediatric oncology publications: A cross-sectional analysis. New research explains why immunotherapy is less effective in children with cancer. Epigenetic states during development establish cancer risk before birth. Teens with cancer report worse pain, mental health a year after advance [...] Read more

Assorted News from the Last Week: A large number of CAC2 members contributed to the recently published conclusions from the 2024 paediatric strategy forum for medicinal product development in diffuse midline gliomas: to achieve progress: i) drug discovery; ii) new multi-modality, efficient, collaborative, pre-clinical approaches, possibly including artificial intelligence and, iii) efficient clinical trial designs fit for regulatory purposes are required. The FDA approved treosulfan (Grafapex) with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation in patients ages 1 year and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Researchers have determined how children's immune [...] Read more

Assorted News from the Last Week: The U.S. Food and Drug Administration (FDA) approved FoundationOne®CDx as a companion diagnostic for Supporting Organization Member Day One Biopharmaceuticals’ OJEMDA, a type II RAF inhibitor, for the treatment of patients six months of age and older with relapsed or refractory pediatric low-grade glioma (pLGG) harboring a BRAF fusion or rearrangement. Pediatric patients with cancer who have obesity at the time of diagnosis may face an elevated risk of mortality. About 30% of adolescents and young adults with cancer who wanted to die at home did not do so. Cancer burden is shifting from [...] Read more